HYDROCORTISONE SODIUM SUCCINATE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Hydrocortisone Sodium Succinate, and what generic alternatives are available?
Hydrocortisone Sodium Succinate is a drug marketed by Abraxis Pharm, Baxter Hlthcare, Cipla, Intl Medication, and Watson Labs. and is included in fifteen NDAs.
The generic ingredient in HYDROCORTISONE SODIUM SUCCINATE is hydrocortisone sodium succinate. There are sixty-seven drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the hydrocortisone sodium succinate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Hydrocortisone Sodium Succinate
A generic version of HYDROCORTISONE SODIUM SUCCINATE was approved as hydrocortisone sodium succinate by CIPLA on September 5th, 2024.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for HYDROCORTISONE SODIUM SUCCINATE?
- What are the global sales for HYDROCORTISONE SODIUM SUCCINATE?
- What is Average Wholesale Price for HYDROCORTISONE SODIUM SUCCINATE?
Summary for HYDROCORTISONE SODIUM SUCCINATE
US Patents: | 0 |
Applicants: | 5 |
NDAs: | 15 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 109 |
Clinical Trials: | 26 |
Patent Applications: | 3,352 |
DailyMed Link: | HYDROCORTISONE SODIUM SUCCINATE at DailyMed |
Recent Clinical Trials for HYDROCORTISONE SODIUM SUCCINATE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
University Medical Center Groningen | Early Phase 1 |
Andrew E. Place | Phase 1 |
Children's Cancer Research Fund | Phase 1 |
Pharmacology for HYDROCORTISONE SODIUM SUCCINATE
Drug Class | Corticosteroid |
Mechanism of Action | Corticosteroid Hormone Receptor Agonists |
Anatomical Therapeutic Chemical (ATC) Classes for HYDROCORTISONE SODIUM SUCCINATE
US Patents and Regulatory Information for HYDROCORTISONE SODIUM SUCCINATE
HYDROCORTISONE SODIUM SUCCINATE is protected by zero US patents and one FDA Regulatory Exclusivity.
FDA Regulatory Exclusivity protecting HYDROCORTISONE SODIUM SUCCINATE
COMPETITIVE GENERIC THERAPY
Exclusivity Expiration: ⤷ Sign Up
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Abraxis Pharm | HYDROCORTISONE SODIUM SUCCINATE | hydrocortisone sodium succinate | INJECTABLE;INJECTION | 088670-001 | Jun 8, 1984 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Baxter Hlthcare | HYDROCORTISONE SODIUM SUCCINATE | hydrocortisone sodium succinate | INJECTABLE;INJECTION | 086619-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Abraxis Pharm | HYDROCORTISONE SODIUM SUCCINATE | hydrocortisone sodium succinate | INJECTABLE;INJECTION | 088668-001 | Jun 8, 1984 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Watson Labs | HYDROCORTISONE SODIUM SUCCINATE | hydrocortisone sodium succinate | INJECTABLE;INJECTION | 084748-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Baxter Hlthcare | HYDROCORTISONE SODIUM SUCCINATE | hydrocortisone sodium succinate | INJECTABLE;INJECTION | 087567-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |